Phase I/II Study of the Safety and Efficacy of the AKT Inhibitor GSK2141795 in Combination with the BRAF Inhibitor Dabrafenib in Patients with BRAF Mutant Cancer
To assess the safety of dabrafenib and GSK2141795 (the study drug) and determine the optimal dose of the study drug in patients with BRAF mutant metastatic melanoma.
Melanoma with BRAF mutations
1. BRAF mutant metastatic melanoma.
2. Melanoma that has progressed after prior therapy.
3. Must be willing to submit tumor tissue from a previous biopsy or undergo a biopsy to obtain fresh tissue for research studies.
4. Other criteria apply.
18 - 100
Healthy Volunteers Needed
Duration of Participation
Until your cancer gets worse or you develop unacceptable side effects
Knight Clinical Trials Information Line